ORIFARM GENERICS A/S: Financial statements 2024
CVR: 25674030
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ORIFARM GENERICS A/S (CVR 25674030) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 2,343,003,000 and a net result of DKK 59,860,000 compared with DKK 62,928,000 the year before. That is an increase of 9.6% compared with the year before. The profit margin was 2.6%. Equity in the 2024 report amounted to DKK 554,507,000. The solvency ratio was 53.3%. The company had 289 employees in the financial year.
- Revenue
- DKK 2,343,003,000
- Gross Profit
- DKK 362,041,000
- Profit/Loss
- DKK 59,860,000
- Equity
- DKK 554,507,000
- Total Assets
- DKK 1,040,284,000
- Employees
- 289
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 2.3B | 362M | 59.9M | 554.5M | 289 |
| 2023 | 2.1B | 344.5M | 62.9M | 494.6M | 289 |
| 2022 | 2.1B | 261.5M | 54.5M | 431.7M | 228 |
| 2021 | 1.8B | 329.3M | 150.1M | 527.3M | 181 |
| 2020 | 688.4M | 274.2M | 145.5M | 201.2M | 117 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ORIFARM GENERICS A/S has won the tender "Amgros 2025 2.210.a" issued by Amgros I/S worth 36,886,685 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 2.1310.b" issued by Amgros I/S worth 129,999,998 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1391.b" issued by Amgros I/S worth 74,708,177 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.700.a" issued by Amgros I/S worth 313,301,544 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1390.b" issued by Amgros I/S worth 27,640,446 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1290.b" issued by Amgros I/S worth 10,863,807 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1207.b" issued by Amgros I/S worth 9,080,000 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1204.b" issued by Amgros I/S worth 9,670,700 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1306.b" issued by Amgros I/S worth 18,679,198 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 2.703.b" issued by Amgros I/S worth 183,298,522 DKK.
About ORIFARM GENERICS A/S
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named COPYFARM A/S and A/S PSE 38 NR. 2228. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 255 employees (2026). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.